LADENBURG THALM/SH SH Raises Brainsway (NASDAQ:BWAY) Price Target to $18.80

Posted by Stanley Muller on Aug 13th, 2026

Brainsway (NASDAQ:BWAY – Get Free Report) had its price target raised by LADENBURG THALM/SH SH from $18.00 to $18.80 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s price target points to a potential upside of 12.54% from the stock’s previous close.

A number of other equities research analysts have also issued reports on BWAY. HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Brainsway in a research report on Friday, July 17th. Zacks Research downgraded Brainsway from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Brainsway in a research note on Tuesday, July 21st. BTIG Research boosted their price objective on shares of Brainsway from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, New Street Research reissued a “buy” rating on shares of Brainsway in a research report on Friday, July 24th. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Brainsway currently has a consensus rating of “Moderate Buy” and an average target price of $16.95.

Get Our Latest Research Report on BWAY

Brainsway Stock Performance

NASDAQ BWAY traded up $0.10 on Thursday, reaching $16.70. The company had a trading volume of 160,956 shares, compared to its average volume of 165,856. The company’s fifty day moving average is $15.08 and its 200-day moving average is $14.33. The firm has a market capitalization of $670.37 million, a price-to-earnings ratio of 48.02 and a beta of 1.24. Brainsway has a 1-year low of $6.26 and a 1-year high of $17.40.

Brainsway (NASDAQ:BWAY – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.04. The firm had revenue of $17.11 million for the quarter, compared to the consensus estimate of $16.54 million. Brainsway had a return on equity of 12.28% and a net margin of 15.68%. On average, research analysts forecast that Brainsway will post 0.33 earnings per share for the current year.

Institutional Investors Weigh In On Brainsway

Hedge funds have recently bought and sold shares of the company. Y.D. More Investments Ltd lifted its position in shares of Brainsway by 136.6% in the first quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock valued at $3,615,000 after buying an additional 157,042 shares during the last quarter. Masters Capital Management LLC boosted its stake in shares of Brainsway by 65.0% during the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock worth $21,928,000 after acquiring an additional 650,000 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Brainsway by 87.2% during the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock worth $6,890,000 after acquiring an additional 241,560 shares during the last quarter. Sei Investments Co. increased its holdings in shares of Brainsway by 262.5% during the 1st quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock worth $3,009,000 after acquiring an additional 163,925 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in Brainsway in the 1st quarter valued at $433,000. 30.11% of the stock is currently owned by institutional investors and hedge funds.

More Brainsway News

Here are the key news stories impacting Brainsway this week:

Positive Sentiment: BrainsWay reported second-quarter 2026 revenue of $17.1 million, up 35% year over year and ahead of the $16.54 million analyst consensus. Adjusted EPS of $0.14 also exceeded expectations of $0.10, reinforcing the company’s improving profitability. BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
Positive Sentiment: Management issued fiscal 2026 revenue guidance of $68 million to $70 million, slightly above the $67.8 million consensus estimate. The guidance suggests continued demand and gives investors greater confidence in the company’s growth outlook.
Positive Sentiment: BTIG Research raised its price target to $20 from $18 and maintained a “buy” rating, implying additional upside from recent trading levels. BTIG Raises BrainsWay Price Target
Positive Sentiment: The earnings beat and growth outlook helped BWAY set a new one-year high, indicating strong investor momentum following the results. Brainsway Sets New One-Year High Following Strong Earnings
Neutral Sentiment: BrainsWay’s earnings call provided additional details on its second-quarter performance and outlook. BrainsWay Q2 2026 Earnings Call Transcript
Negative Sentiment: Zacks Research downgraded BWAY from “strong buy” to “hold.” The call is a more cautious signal after the recent rally and could weigh on near-term upside, despite the company’s strong fundamentals. Zacks Research

Brainsway Company Profile

(Get Free Report)

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.